Skip to main content
Industry News
FDA guidance targets adverse event reporting during trials

The FDA has updated its guidance for adverse event reporting in clinical trials conducted during the COVID-19 pandemic. For example, in trials of approved drugs being studied for COVID-19, companies must report spontaneous reports of serious adverse events related to the drug's off-label use in clinical practice to treat COVID-19.

Full Story: